Wave Life Sciences .(US:WVE) 智通财经网·2025-12-08 14:54Core Viewpoint - Wave Life Sciences' stock surged nearly 80% to a new yearly high of $13.42 following positive mid-term results from its Phase 1 trial of WVE-007 for obesity treatment, showing promising weight loss effects without muscle loss [1] Group 1: Clinical Trial Results - The mid-term data from the Phase 1 trial of WVE-007 indicated improvements in body composition, with a weight loss effect comparable to GLP-1 at the lowest treatment dose [1] - A single 240 mg dose of WVE-007 resulted in a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean body mass [1] - The overall safety and tolerability of WVE-007 were confirmed, with only mild treatment-related adverse events reported [1] Group 2: Future Expectations - Wave Life Sciences anticipates releasing further clinical data updates in the first quarter of 2026, which will include six-month follow-up data for the 240 mg single-dose group [1]